Edition:
United States

Acasti Pharma Inc (ACST.OQ)

ACST.OQ on NASDAQ Stock Exchange Capital Market

1.28USD
11:41am EDT
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.28
Open
$1.28
Day's High
$1.28
Day's Low
$1.27
Volume
4,902
Avg. Vol
25,598
52-wk High
$3.09
52-wk Low
$1.11

Latest Key Developments (Source: Significant Developments)

Acasti Pharma says CaPre Phase 3 on track to start in late 2017
Thursday, 30 Mar 2017 08:15am EDT 

Acasti Pharma Inc : Acasti Pharma provides update on capre phase 3 development program . Confirms phase 3 program is on track to start late 2017 .Acasti Pharma - FDA's feedback supports co's plan to conduct two studies instead of one large study, potentially shortening time to NDA submission.  Full Article

Acasti Pharma announces pricing for its public offering of units
Friday, 10 Feb 2017 04:26pm EST 

Acasti Pharma Inc : Acasti Pharma announces pricing for its public offering of units .Acasti Pharma- entered agency agreement with Echelon Wealth Partners as sole bookrunner, lead agent; agent to offer units for proceeds of C$4.5 million-C$8 million.  Full Article

Acasti Pharma Q3 loss C$0.22/shr
Thursday, 12 Jan 2017 05:15pm EST 

Acasti Pharma Inc : Acasti Pharma reports third quarter 2017 financial results . Q3 loss per share C$0.22 . Acasti pharma - Had cash,short-term investments of $5.8 million as of Nov 30, 2016 .Acasti Pharma - if co doesn't raise additional funds, there exists material uncertainty casting substantial doubt about ability to continue as going concern.  Full Article

Acasti Pharma announces proposed offering of units
Monday, 5 Dec 2016 05:38pm EST 

Acasti Pharma Inc : Acasti Pharma announces proposed offering of units .Acasti Pharma-Received receipt for a preliminary short form prospectus for minimum gross proceeds of CAD$6.5 million, maximum gross proceeds of CAD$10 million.  Full Article

Acasti Pharma Q2 loss per share $0.22
Tuesday, 11 Oct 2016 05:00pm EDT 

Acasti Pharma Inc : reports second quarter 2017 financial results . Qtrly loss per share $0.22 . if co does not raise additional funds, there exists uncertainty that casts substantial doubt about ability to continue as going concern .Management has reasonable expectation that corporation will be able to raise additional funds.  Full Article

Acasti posts qtrly loss per share of $0.29
Monday, 11 Jul 2016 05:30pm EDT 

Acasti Pharma Inc: Acasti announces first quarter results .Qtrly loss per share $0.29.  Full Article

Acasti Pharma says Jan D'Alvise named as CEO
Thursday, 12 May 2016 08:08am EDT 

Acasti Pharma Inc : Says Jan D'Alvise appointed as president and chief executive officer effective June 1, 2016 .Jan D'Alvise appointed president & CEO of Acasti Pharma.  Full Article

Acasti Pharma Inc says appointment of Roderick Carter, as Executive Chairman of the Board
Tuesday, 1 Mar 2016 08:00am EST 

Acasti Pharma Inc:Says appointment of Roderick Carter, as Executive Chairman of the Board.  Full Article

More From Around the Web

BRIEF-Acasti Pharma says has successfully completed two Phase 1, two Phase 2 clinical trials with Capre

* Acasti Pharma Inc - has successfully completed two Phase 1 and two Phase 2 clinical trials with Capre for treatment of hypertriglyceridemia